Skip to main content

Table 1 Patients included in the study

From: Adipose tissue derived stem cells: in vitro and in vivo analysis of a standard and three commercially available cell-assisted lipotransfer techniques

 

Standard lipoaspirate

ASC-enriched lipoaspirate

Statistical significance

ASC-enriched lipoaspirate technique

 

Cytori

Lipokit

Fastem

Clinical features

      

n (%)

16 (44.4%)

20 (55%)

 

9 (25%)

5 (13.8%)

6 (16.7%)

Age (years)

49.5 (21 to 71)

48 (19 to 74)

P = 0.8370

46 (41 to 70)

52 (41 to 57)

52 (19 to 74)

BMI (kg/m2)

22.35 (19.36 to 30.3)

21.4 (19.8 to 32.8)

P = 0.7520

21.30 (20.58 to 30.5)

22.19 (20 to 32.8)

21.20 (19.8 to 24.4)

Co-morbidities

0 (0.0%)

2 (10.0%)

P = 0.4921

1 (11.1%)

1 (20.0%)

0 (0.0%)

Previous surgical procedure

Mastectomy

14 (87.50%)

16 (80.00%)

P = 0.6722

8 (89%)

5 (100%)

3 (50%)

Quadrantectomy

1 (6.25%)

2 (10.00%)

P = 1.0000

1 (11.1%)

0 (0.00%)

1 (16.7%)

None (congenital malformation)

1 (6.25%)

2 (10.00%)

P = 1.0000

0 (0.00%)

0 (0.00%)

2 (33.3%)

Donor area

      

Abdomen

5 (31.25%)

1 (5.00%)

P = 0.0689

0 (0.00%)

0 (0.00%)

1 (16.7%)

Hips

7 (43.75%)

7 (35.00%)

chi-q = 0.5926

3 (22.2%)

3 (60%)

1 (16.7%)

Trochanteric region

2 (12.50%)

2 (10.00%)

P = 1.0000

1 (11.1%)

0 (0.00%)

1 (16.7%)

Abdomen and hips

2 (12.50%)

4 (20%)

P = 0.6722

1 (11.1%)

2 (40%)

1 (16.7%)

Hips and trochanteric region

0 (0.00%)

4 (20%)

P = 0.1131

3 (22.2%)

0 (0.00%)

1 (16.7%)

Abdomen and trochanteric region

0 (0.00%)

1 (5.00%)

P = 1.0000

0 (0.00%)

0 (0.00%)

1 (16.7%)

Abdomen. hips and trochanteric region

0 (0.00%)

1 (5.00%)

P = 1.0000

1 (11.1%)

0 (0.00%)

0 (0.00%)

Amount of solution infiltrated (cm3)

95 (54 to 160)

143 (60 to 230)

P = 0.0540

158 (75 to 230)

145 (60 to 175)

85 (75 to 165)

Adjuvant therapies

None

6 (37.5%)

11 (55%)

P = 0.3351

5 (55.6%)

2 (40%)

4 (66.7%)

RT

1 (6.25%)

3 (15.00%)

P = 0.6129

1 (11.1%)

1 (20%)

1 (16.7%)

CT

7 (43.75%)

3 (15.00%)

P = 0.0732

1 (11.1%)

2 (40%)

0 (0.00%)

RT and CT

2 (12.50%)

3 (15.00%)

P = 1.0000

2 (22.2%)

0 (0.00%)

1 (16.7%)

Hormonal therapies

7 (43.75%)

12 (60.00%)

chi-q = 0.3318

6 (67%)

4 (80%)

2 (33.3%)

  1. Data presented as median (range) or n (%). ASC, adipose stem cell; BMI, body mass index; CT, chemotherapy; Cytori, Cytori Celution System (Cytori Ltd., Deeside, UK) [25]; Fastem, Fastem Corios (CORIOS Soc. Coop, San Giuliano Milanese (MI), Italy); Lipokit, Lipokit Medikhan System (Medikan International Inc, Pusan, Korea) [26]; RT, radiotherapy.